Millennium: The Takeda Oncology Company
40 Landsdowne Street
Cambridge
Massachusetts
02139
U.S.A.
Phone:
617-679-7000
Fax:
617-374-7788
|
About Millennium
Millennium: The Takeda Oncology Company, is a leading biopharmaceutical company based in Cambridge, Mass., Millennium was established in 1993 as a genomics company (Millennium Pharmaceuticals, Inc.) and has grown into a fully-integrated biopharmaceutical company with a pipeline of innovative molecules focused in oncology.
Our business begins and ends with the quality of our science. We take deep pride in the world class quality of both our discovery and development science (R&D). Our science has been instrumental in producing medicine that makes a real difference in patients’ lives.
Our company markets VELCADE® (bortezomib) for Injection, a leading global cancer therapy for the treatment of patients with multiple myeloma and relapsed mantle cell lymphoma. VELCADE is co-developed by Millennium and Janssen Pharmaceutical Companies. Millennium is responsible for commercialization of VELCADE in the U.S.; Janssen Pharmaceutical Companies are responsible for commercialization in Europe and the rest of the world. Takeda Pharmaceutical Company Limited and Janssen Pharmaceutical K.K. co-promote VELCADE in Japan. VELCADE is approved in more than 90 countries and has been used to treat more than 350,000 patients worldwide.
Millennium Pharmaceuticals, Inc. was acquired by Takeda Pharmaceutical Company Ltd. in May, 2008. Located in Osaka, Japan, Takeda is a research-based global company with its main focus on pharmaceuticals. As the largest pharmaceutical company in Japan and one of the global leaders of the industry, Takeda is committed to strive towards better health for patients worldwide through leading innovation in medicine.
Along with our increased capacity in oncology comes an increased accountability for success. Our goal is to become a global leader in providing medicines that fundamentally improve the lives of patients with cancer. Specifically, our aim is to be a top-three global oncology company by 2020. In the most competitive of therapeutic categories, this is an audacious goal, but one worthy of Millennium and Takeda.
Additional information about Millennium is available through its website, www.millennium.com.
Email:
info@mlnm.com
Ownership:
Public
Web Site:
Millennium: The Takeda Oncology Company
Employees:
1400
Symbol:
|